Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

7.020 +0.500 (+7.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 731,085
Open 6.510
Bid (Size) 6.700 (1)
Ask (Size) 8.500 (5)
Prev. Close 6.520
Today's Range 6.415 - 7.130
52wk Range 5.350 - 17.58
Shares Outstanding 44,188,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics
Via Benzinga

Performance

YTD
-37.7%
-37.7%
1 Month
-17.6%
-17.6%
3 Month
-22.0%
-22.0%
6 Month
-40.7%
-40.7%
1 Year
-48.0%
-48.0%

More News

Read More
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts
Via Benzinga
Stoke Therapeutics Announces CEO Transition
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Via Benzinga
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics
Via Business Wire
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?
Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?
Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?
The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market
What is the current price of Stoke Therapeutics, Inc. - Common Stock?
The current price of Stoke Therapeutics, Inc. - Common Stock is 7.020
When was Stoke Therapeutics, Inc. - Common Stock last traded?
The last trade of Stoke Therapeutics, Inc. - Common Stock was at 04/11/25 04:00 PM ET
What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 310.20M
How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
Stoke Therapeutics, Inc. - Common Stock has 310M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.